
Downloaded from: http://researchonline.lshtm.ac.uk/12840/

DOI: 10.1002/14651858.CD000567.pub2

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the author(s)
Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)

Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2004, Issue 4

http://www.thecochranelibrary.com

WILEY
Colloids versus crystalloids for fluid resuscitation in critically ill patients

I Roberts, P Alderson, F Bunn, P Chinnock, K Ker, G Schierhout

Contact address: Mr Paul Chinnock, Senior Editor, PLoS Medicine, 7 Portugal Place, Cambridge, CB5 8AF, UK. pchinnock@plos.org.

Editorial group: Cochrane Injuries Group.
Review content assessed as up-to-date.


ABSTRACT

Background
Colloid solutions are widely used in fluid resuscitation of critically ill patients. There are several choices of colloid and there is ongoing debate about the relative effectiveness of colloids compared to crystalloid fluids.

Objectives
To assess the effects on mortality of colloids compared to crystalloids for fluid resuscitation in critically ill patients.

Search strategy
We searched the Injuries Group specialised register, Cochrane Controlled Trials Register, MEDLINE, EMBASE and BIDS Index to Scientific and Technical Proceedings, and checked reference lists of trials and review articles.

Selection criteria
All randomised and quasi-randomised trials of colloids compared to crystalloids, in patients requiring volume replacement. Cross-over trials and trials in pregnant women and neonates were excluded.

Data collection and analysis
Two reviewers independently extracted data and rated quality of allocation concealment. Trials with a ‘double-intervention’, such as those comparing colloid in hypertonic crystalloid to isotonic crystalloid, were analysed separately. The analysis was stratified according to colloid type and quality of allocation concealment.

Main results
Colloids compared to crystalloids
Albumin or plasma protein fraction. Nineteen trials reported data on mortality, including a total of 7576 patients. The pooled relative risk (RR) from these trials was 1.02 (95% confidence interval [95% CI] 0.93 to 1.11). When the trial with poor quality allocation concealment was excluded, pooled RR was 1.01 (95% CI 0.92 to 1.10).

Hydroxyethyl starch. Ten trials compared hydroxyethyl starch with crystalloids, including a total of 374 randomised participants. The pooled RR was 1.16 (95% CI 0.68 to 1.96).

Modified gelatin. Seven trials compared modified gelatin with crystalloid, including a total of 346 randomised participants. The pooled RR was 0.54 (95% CI 0.16 to 1.85).
Dextran. Nine trials compared dextran with a crystalloid, including a total of 834 randomised participants. The pooled relative risk was RR 1.24 (95% CI 0.94 to 1.65).

Colloids in hypertonic crystalloid compared to isotonic crystalloid

Eight trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1283 randomised participants. Pooled RR was 0.88 (95% CI 0.74 to 1.05).

Authors’ conclusions

There is no evidence from randomised controlled trials that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids, in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and as they are more expensive than crystalloids, it is hard to see how their continued use in these patients can be justified outside the context of randomised controlled trials.

PLAIN LANGUAGE SUMMARY

No evidence that colloids are more effective than crystalloids in reducing mortality in people who are critically ill or injured

Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein) to replace lost blood, is used to try to maintain blood pressure and reduce the risk of dying. Blood products, non-blood products or combinations are used, including colloid or crystalloid solutions. Colloids are increasingly used but they are more expensive than crystalloids. The review of trials found no evidence that colloids reduce the risk of dying compared with crystalloids.

BACKGROUND

Fluid resuscitation for hypovolaemia is a mainstay of the medical management of critically ill patients, whether as a result of trauma, burns, major surgery or sepsis. Although recent studies (Bickell 1994) have suggested that the timing of volume replacement deserves careful consideration, when it comes to selecting the resuscitation fluid clinicians are faced with a range of options. At one level the choice is between a colloid or crystalloid solution. Colloids are widely used, having been recommended in a number of resuscitation guidelines and intensive care management algorithms (Vermeulen 1995; Armstrong 1994). The US Hospital Consortium Guidelines recommend that colloids are used in haemorrhagic shock prior to the availability of blood products, and in non-haemorrhagic shock following an initial crystalloid infusion. A 1995 survey of US academic health centres, however, found that the use of colloids far exceeded even the Hospital Consortium recommendations (Yim 1995). Surveys of burn care in the US (Fakhry 1995) and in Australia (Victorian DUAC 1991) found that the use of colloids for resuscitation varied without a set pattern. The choice of fluid has considerable cost implications. Volume replacement with colloids is considerably more expensive than with crystalloids. Clinical studies have shown that colloids and crystalloids have different effects on a range of important physiological parameters. Because of these differences, all-cause mortality is arguably the most clinically relevant outcome measure in randomised trials comparing the two fluid types. Although there have been previous meta-analyses of mortality in randomised trials comparing colloids and crystalloids (Velanovich 1989, Bisonni 1991), neither of these satisfy the criteria that have been proposed for scientific overviews (Oxman 1994), and they predate most of the trials that have been conducted using synthetic colloids, and hypertonic crystalloid solutions. The purpose of this review is to identify and synthesise all available unconfounded evidence of the effect on mortality in critically ill patients of colloids compared to crystalloids for volume replacement.

OBJECTIVES

To determine the effects on mortality of using colloids compared to crystalloids, during fluid resuscitation in critically ill patients.

RESULTS

Colloids compared to crystalloids

Albumin or plasma protein fraction

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Twenty trials reported data on mortality, including a total of 7576 patients. The pooled RR from these trials was 1.02 (95% CI 0.93 to 1.11). When the one trial with poor quality allocation concealment (Lucas 1978) was excluded, the pooled RR was 1.01 (95% CI 0.92 to 1.01).

**Hydroxyethyl starch**

Ten trials compared hydroxyethyl starch with crystalloids, including a total of 374 randomised participants. The pooled RR was 1.16 (95% CI 0.68 to 1.96).

**Modified gelatin**

Seven trials compared modified gelatin with crystalloid, including a total of 346 randomised participants. The pooled RR was 0.54 (95% CI 0.16 to 1.85).

**Dextran**

Nine trials compared dextran with a crystalloid, including a total of 834 randomised participants. The pooled RR was 1.24 (95% CI 0.94 to 1.65).

**Colloids in hypertonic crystalloid compared to isotonic crystalloid**

One trial compared albumin and hypertonic saline with isotonic crystalloid. Its relative risk of death was 0.50 (0.06 to 4.33).

Eight trials compared dextran in hypertonic crystalloid with isotonic crystalloid, including 1283 randomised participants. The pooled RR was 0.88 (0.74 to 1.05).

**Colloids in isotonic crystalloid compared to hypertonic crystalloid**

Three trials compared colloids in isotonic crystalloid with hypertonic crystalloid. In two of these, where the colloid was either gelatin or starch, there were no deaths in either group. In the remaining trial, with 38 participants, there was a relative risk of death of 7.00 (0.39 to 126.93) for use of colloid, based on three deaths in the treatment group and none in the control group.

**DISCUSSION**

This systematic review synthesises the evidence from randomised controlled trials comparing colloid and crystalloid fluid resuscitation across a wide variety of clinical conditions. The review has been updated and extensively revised to take into account the comments made since it was first published. In particular, several commentators pointed out that it is inappropriate to combine effect estimates from studies of different colloids. For example, it was argued that large molecular weight colloids such as hydroxyethyl starch may be better retained in the vascular compartment than albumin and gelatins, and would therefore be more likely to show a favourable effect on mortality (Gosling 1998). In response to these concerns, the review has been stratified by type of colloid. However, the pooled relative risks fail to show a mortality benefit for resuscitation with any type of colloid.

There was a trend towards a favourable effect on mortality for colloids in hypertonic crystalloid, compared to isotonic crystalloids. Nevertheless, the results are compatible with the play of chance.

Common to all meta-analyses, this systematic review may have included studies whose interventions and patient characteristics are sufficiently incomparable that the calculation of a summary effect measure may be questioned. The resuscitation regimen differed between trials. Some trials randomised participants to an initial quantity of colloid or crystalloid, and then proceeded with some form of standard resuscitation for all participants. Other trials resuscitated with the allocated fluid to predetermined end-points, either resuscitation end-points, or in the case of trauma, until corrective surgery. In addition, the type of colloid or crystalloid, the concentration, and the protocol to determine the quantity of fluid varied. Despite these differences, all participants were in need of volume replacement, and we believe that this variation in the intervention would have an impact on the size of the effect, rather than on its direction.

As regards the effects of albumin versus crystalloid, most of the information (as indicated by the weighting in the meta-analysis) was provided by the SAFE trial. The SAFE trial used central randomisation with a minimisation algorithm to ensure balance on known potential confounders. Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the masking was confirmed in a formal study before the trial was initiated. In brief, this was a well-conducted, high-quality trial. There were 726 deaths (20.9%) in the albumin-treated group and 729 deaths (21.1%) in the saline-treated group (RR of death 0.99; 95% CI 0.91 to 1.09). Although even this large trial was unable to confirm or refute the possibility of a modest benefit or harm from albumin, it has provided some reassurance that any hazard from albumin, if indeed there is any, is unlikely to be as extreme as was suggested by the results from the previously published (now here updated) meta-analysis of much smaller trials. The pooled relative risk for death with albumin in this updated meta-analysis is now 1.02 (0.93 to 1.11). It is important to note that the effect estimate from the SAFE trial is entirely consistent with the results of previous trials of albumin in hypovolaemia and there is no significant heterogeneity ($I^2$ =0%, $p=0.46$).

The results of this updated meta-analysis have important policy implications. There is still no evidence that colloids are superior to crystalloids as a treatment for intravascular volume resuscitation in critically ill patients. Importantly, the SAFE trial also provided no evidence of any other clinical advantages from using albumin. It also debunked the belief, from pathophysiological inference, that very large volumes of crystalloid must be administered to reach...
the same resuscitation end-points as can be achieved using much smaller volumes of colloid. In the SAFE trial, the ratio of albumin administered to saline administered was approximately 1:1.4. Colloids, in particular albumin, are considerably more expensive than crystalloids, and albumin is a blood product and so carries at least a theoretical infectious disease risk. The economic opportunity cost of on-going colloid use, particularly albumin use, is likely to be considerable and for this reason its on-going use in this context is unjustified.

AUTHORS’ CONCLUSIONS

Implications for practice

There is no evidence from randomised controlled trials that resuscitation with colloids, instead of crystalloids, reduces the risk of death in patients with trauma, burns or following surgery. As colloids are not associated with an improvement in survival, and further, colloids are considerably more expensive than crystalloids, it is hard to see how their continued use outside the context of randomised controlled trials in subsets of patients of particular concern, can be justified.

Implications for research

Future trials may need to concentrate on specific sub-groups of patients to identify people who may benefit from colloids rather than crystalloids.

ACKNOWLEDGEMENTS

We would like to acknowledge the Intensive Care National Audit and Research Network in London, for assistance with identification of trials for this review.

REFERENCES

References to studies included in this review

Boldt 1986 [published data only]

Boldt 1993 [published data only]

Boldt 2001 [published data only]

Boutros 1979 [published data only]

Bowser-Wallace 1986 [published data only]

Bowser-Wallace 1996 [published and unpublished data]


Chavez-Negrete 1991 [published data only]

Dawidson 1991 [published data only]

Dehne 2001 [published data only]

Eleftheriadis 1995 [published data only]

Ernest 1999 [published data only]

Evans 1996 [published and unpublished data]
Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Gallagher 1985 [published data only]
Gallagher JD, Moore RA, Kerns D, Jose AB, Botros SB, Flicker S, Naidech H, Clark DL. Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. Anesthesia and Analgesia 1985;64(8):753–8.

Goodwin 1983 [published data only]

Grundmann 1982 [published data only]

Karanko 1987 [published data only]

Lowe 1977 [published data only]

Lucas 1978 [published data only]

Mazher 1998 [published data only]
Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

McNulty 1993 [published data only]

Metildi 1984 [published data only]

Nagy 1993 [published data only]

Ngo 2001 [published data only]

Nielson 1985 [published data only]

Pockaj 1994 [published data only]

Prien 1990 [published data only]

Rackow 1983 [published data only]

Rackow 1984 [published data only]

SAFE 2004 [published data only]

Shah 1977 [published data only]

Siricix 1999 [published data only]

Skillman 1975 [published data only]

Tollofsrud 1995 [published data only]

Tollofsrud 1998 [published data only]

Vassar 1990 [published data only]

Vassar 1991 [published data only]
Holcroft JW, Vassar MJ, Turner JE, Derer LW, Kramer GC. 3% NaCl and 7.5% NaCl/dextran 70 in the resuscitation


Vassar 1993a  [published data only]

Vassar 1993b  [published data only]

Virgilio 1979  [published data only]

Wahba 1996  [published data only]

Woittiez 1997  [published and unpublished data]

Wu 2001  [published data only]

Younes 1992  [published data only]

Younes 1994  [published data only]

Younes 1998  [published data only]

Zetterstrom 1981a  [published data only]

Zetterstrom 1981b  [published data only]

References to studies excluded from this review

Artru 1989

Bocanegra 1966

Boldt 1996

Bothner 1998

Brechme 1993

Golub 1994

Goslinga 1992
Goslinga H, Eijzenbach V, Heuvelmans JH, van de Nes JC, Kuzk RM, Bezem P. Individualized hemodilution in acute brain infarcit using a 20% albumin solution and...


Greenhalgh 1995

Hauser 1980

Lagonidis 1995

Marhofer 1999

Nilsson 1980

Rehm 2001

Steinberg 1989

Wilkes 2001

Woods 1993

References to studies awaiting assessment

Bueno R 2004

Oliviera 2002

Paul 2003

Additional references

Albumin 2004

Armstrong 1994

Bickell 1994

Bisonni 1991

Fakhry 1995

Gosling 1998

Oxman 1994

Schulz 1995
Schulz KE, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of

**Velanovich 1989**

**Vermeulen 1995**

**Victorian DUAC 1991**

**Yim 1995**

**References to other published versions of this review**

**Schierhout 1998**

* Indicates the major publication for the study

**Sources of Support**

**External sources of support**
- NHS R&D Programme: Mother and Child Health UK

**Internal sources of support**
- Institute of Child Health, University of London UK
- UK Cochrane Centre, NHS R&D Programme UK

**Index Terms**

**Medical Subject Headings (MeSH)**
Colloids [*therapeutic use*]; Critical Illness [*therapy*]; Fluid Therapy [*methods*]; Plasma Substitutes [*therapeutic use*]; Randomized Controlled Trials; *Rehydration Solutions; Resuscitation [methods]*

**MeSH check words**
Humans